TOKYO (dpa-AFX) - Vical Inc. (VICL) announced the U.S. FDA has granted the
company Fast Track designation for its investigational antifungal product
candidate, VL-2397, for the treatment of invasive aspergillosis.
Larry Smith, Vical's Vice...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vical (VICL):